Compounds blocking mutant huntingtin toxicity identified using a Huntington's disease neuronal cell model.

作者: Wenfei Wang , Wenzhen Duan , Shuichi Igarashi , Hokuto Morita , Masayuki Nakamura

DOI: 10.1016/J.NBD.2005.03.026

关键词:

摘要: Neuronal cell death in HD is believed to be largely a dominant cell-autonomous effect of the mutant huntingtin protein. We previously developed an inducible PC12 model which expresses N-terminal fragment with expanded poly Q repeat (N63-148Q) under control tet-off system. In order evaluate ability compounds protect against toxicity our model, we measured LDH released by dead cells into medium. have now screened library 1040 from NINDS Custom Collection as part National Institute Neurological Disorders and Stroke (NINDS) collaborative project. Each positive compound was tested at 3-8 concentrations. Five significantly attenuated (htt)-induced release without affecting expression level independent on aggregates. also broad spectrum caspase inhibitor Z-VAD-fmk proposed candidate compounds. This can provide method screen potential therapeutic for treating Huntington's disease.

参考文章(44)
Robert E. Hughes, James M. Olson, Therapeutic opportunities in polyglutamine disease. Nature Medicine. ,vol. 7, pp. 419- 423 ,(2001) , 10.1038/86486
Alpaslan Dedeoglu, James K. Kubilus, Thomas M. Jeitner, Samantha A. Matson, Misha Bogdanov, Neil W. Kowall, Wayne R. Matson, Arthur J. L. Cooper, Rajiv R. Ratan, M. Flint Beal, Steven M. Hersch, Robert J. Ferrante, Therapeutic effects of cystamine in a murine model of Huntington's disease. The Journal of Neuroscience. ,vol. 22, pp. 8942- 8950 ,(2002) , 10.1523/JNEUROSCI.22-20-08942.2002
E. Hockly, V. M. Richon, B. Woodman, D. L. Smith, X. Zhou, E. Rosa, K. Sathasivam, S. Ghazi-Noori, A. Mahal, P. A. S. Lowden, J. S. Steffan, J. L. Marsh, L. M. Thompson, C. M. Lewis, P. A. Marks, G. P. Bates, Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease Proceedings of the National Academy of Sciences of the United States of America. ,vol. 100, pp. 2041- 2046 ,(2003) , 10.1073/PNAS.0437870100
Toshihiko Tsuda, Youko Ohmori, Hiroyuki Muramatsu, Yoshitaka Hosaka, Kazuhiko Takiguchi, Fumihiko Saitoh, Kazuo Kato, Kazuyuki Nakayama, Norio Nakamura, Shigekazu Nagata, Hidenori Mochizuki, Inhibitory effect of M50054, a novel inhibitor of apoptosis, on anti-Fas-antibody-induced hepatitis and chemotherapy-induced alopecia European Journal of Pharmacology. ,vol. 433, pp. 37- 45 ,(2001) , 10.1016/S0014-2999(01)01489-3
Shuichi Igarashi, Hokuto Morita, Kyla M. Bennett, Yuji Tanaka, Simone Engelender, Matthew F. Peters, Jillian K. Cooper, Jonathan D. Wood, Akira Sawa, Christopher A. Ross, Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation. Neuroreport. ,vol. 14, pp. 565- 568 ,(2003) , 10.1097/00001756-200303240-00007
Blair Leavitt, Cheryl Wellington, Michael Hayden, Recent insights into the molecular pathogenesis of Huntington disease. Seminars in Neurology. ,vol. 19, pp. 385- 395 ,(1999) , 10.1055/S-2008-1040853
Charity T Aiken, Allan J Tobin, Erik S Schweitzer, A cell-based screen for drugs to treat Huntington's disease. Neurobiology of Disease. ,vol. 16, pp. 546- 555 ,(2004) , 10.1016/J.NBD.2004.04.001
Joanna L. Jankowsky, Alena Savonenko, Gabriele Schilling, Jiou Wang, Guilian Xu, David R. Borchelt, Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Current Neurology and Neuroscience Reports. ,vol. 2, pp. 457- 464 ,(2002) , 10.1007/S11910-002-0073-7
Ron R. Kopito, Roopal M. Sampat, Neil F. Bence, Impairment of the ubiquitin proteasome system by protein aggregation ,(2003)